Samarinas Michael, Karatzas Anastasios, Tzortzis Vasileios, Gravas Stavros
Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Mezourlo, 41110 Larissa, Greece.
Department of Urology, General Hospital of Larissa, Tsakalof 1, 41221 Larissa, Greece.
J Clin Med. 2020 Mar 30;9(4):957. doi: 10.3390/jcm9040957.
A randomized biopsy study showed that hexanic (HESr) treatment resulted in prostatic inflammation reduction. This post-hoc analysis evaluated the clinical impact of HESr and investigated correlations between baseline parameters and treatment response. Patients were randomized to receive HESr 320mg/day for six months or no therapy. Assessment included International Prostate Symptoms Score (IPSS), prostate volume (PV), and maximum flow rate (Qmax). Baseline characteristics were recorded, including body mass index (BMI) and metabolic syndrome (MetS) components. In patients under α1-adrenoceptor antagonists (α1-blockers), the addition of HESr resulted in statistically significant IPSS improvement after 6 months ( = 0.006). IPSS remained stable in patients under a1-blockers only ( = 0.346). Patients treated only with HESr reported a significant IPSS amelioration ( = 0.001). In the control group of naïve patients, no significant IPSS change was detected ( = 0.298). Baseline PV showed fair correlation ( = -0.20) with inflammation reduction in the HESr patients. BMI ( = 0.40), diabetes mellitus ( = 0.40), and PV ( = 0.23) showed fair correlation with Qmax increase but without reaching statistical significance. MetS ( = 0.06) was an influent biomarker for Qmax improvement. Treatment with HESr (as monotherapy or add-on therapy to a-blockers) may improve urinary symptoms in terms of IPSS in patients with prostatic inflammation.
一项随机活检研究表明，己烷化（HESr）治疗可减轻前列腺炎症。这项事后分析评估了HESr的临床影响，并研究了基线参数与治疗反应之间的相关性。患者被随机分为两组，一组接受每天320mg的HESr治疗，持续六个月，另一组不接受治疗。评估内容包括国际前列腺症状评分（IPSS）、前列腺体积（PV）和最大尿流率（Qmax）。记录了基线特征，包括体重指数（BMI）和代谢综合征（MetS）的组成部分。在服用α1-肾上腺素能受体拮抗剂（α1-阻滞剂）的患者中，添加HESr在6个月后导致IPSS有统计学意义的改善（P = 0.006）。仅服用α1-阻滞剂的患者IPSS保持稳定（P = 0.346）。仅接受HESr治疗的患者报告IPSS有显著改善（P = 0.001）。在未经治疗的单纯患者对照组中，未检测到IPSS有显著变化（P = 0.298）。基线PV与HESr治疗患者的炎症减轻有中等程度的相关性（P = -0.20）。BMI（P = 0.40）、糖尿病（P = 0.40）和PV（P = 0.23）与Qmax增加有中等程度的相关性，但未达到统计学意义。MetS（P = 0.06）是Qmax改善的一个有影响的生物标志物。HESr治疗（作为单一疗法或α-阻滞剂的附加疗法）可能会改善前列腺炎症患者的IPSS方面的尿路症状。
